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OBJECTIVES: To compare 12-month adherence to liraglutide once daily (QD) or 
exenatide once weekly (QW) between commercially insured patients with type 2 
diabetes mellitus (T2DM) newly initiating liraglutide QD or exenatide QW in the 
U.S. METHODS: This retrospective cohort study used U.S. administrative claims 
data to study patients with T2DM initiating liraglutide QD or exenatide QW (initiated 
therapy= index therapy). Patients were included if they had T2DM, were glucagon-
like peptide-1 receptor agonist (GLP-1RA)–naïve, initiated liraglutide QD or exenatide 
QW from 2/1/2012–10/1/2012 (date of initiation= index), were aged ≥ 18y at index, 
and had continuous enrollment for 12 months before (baseline) to 12 months after 
index (follow-up). The study outcome was index GLP-1RA adherence (proportion 
of days covered [PDC] during follow-up, dichotomized at ≥ 80% versus < 80%, and 
at ≥ 90% versus < 90%). These PDC thresholds have been shown to be predictive of 
reduced hospitalization and mortality for patients with diabetes. Multivariable logis-
tic regressions compared adherence between the GLP-1RAs, adjusting for potential 
confounders. Sensitivity analyses were performed separating liraglutide QD by dose 
(1.2 mg/1.8 mg). RESULTS: Study sample included 10,829 liraglutide QD (4,945 1.2 
mg; 5,884 1.8 mg) patients and 3,173 exenatide QW patients. In each group, mean age 
was approximately 52 years and the proportion of females was 50% for exenatide 
QW and 54% for liraglutide QD. In multivariable-adjusted analyses, liraglutide QD 
patients had statistically significant lower odds of achieving a PDC≥ 80% (odds ratio 
[OR] treating exenatide QW as reference= 0.888, P= .007, 95% confidence interval 
[CI]= 0.816 to 0.968) and statistically significant lower odds of achieving a PDC≥ 90% 
(OR= 0.757, P< .001, 95% CI= 0.690 to 0.831) than exenatide QW patients. In sensitivity 
analyses, results when separating liraglutide QD by dose were directionally consist-
ent. CONCLUSIONS: Patients receiving exenatide QW had greater adjusted odds 
of clinically significant adherence thresholds compared with patients receiving 
liraglutide QD in this retrospective analysis.
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OBJECTIVES: To assess the barriers to treatment adherence on disease manage-
ment of acromegaly from the provider prospective METHODS: A web-based cross-
sectional survey was conducted from August –October, 2014. Healthcare providers 
who had experience in treating acromegaly patients were asked about barriers to 
treatment adherence and influence on the treatment algorithm based on their 
experiences and perspectives. RESULTS: A total of 23 providers (mean age: 56 
years, female: 48%) completed the survey, including physicians (52%), nurses or 
nurse practitioners (43%) and research coordinators (5%). Most worked at academic 
hospitals (78%). Their specialties included endocrinology & metabolism (70%), neu-
roendocrinology (22%) and neurosurgery (8%). Of the providers, 62% had more than 
10 years of experience (range: 5-40 years) treating acromegaly; 75% of them were 
concerned about the barriers to pharmacological treatment adherence. The great-
est concerns were side effects (100%), financial issues (89%), and the therapy being 
too complicated or inconvenient to patients (56%). Seventy percent (5 MDs and 
11 nurses) had encountered patients with symptoms that became worse toward 
the end of an injection cycle, 80% of physicians adjusted the treatment algorithm 
accordingly. Of 9 nurses who had experiences with somatostatin analog (SSA) 
injections, 67% of them raised concerns, of which the most common were side 
effects (e.g., pain, erythema, hematoma), and time loss due to injections. When 
considering the patient’s specific needs, all physicians and nurses with SSA injec-
tion experience (n= 21) would consider offering an oral therapy to patients if it had 
comparable efficacy and safety to the current long acting SSA treatments. The top 
three determinants to drive decisions in acromegaly maintenance therapy were 
clinical guidelines, lower out-of-pocket cost for the patient, and lower total medical 
costs. CONCLUSIONS: Study results indicated that treatment side effects, financial 
issues, and inconvenience were the leading barriers to treatment adherence from 
the healthcare provider perspective.
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OBJECTIVES: Adherence to diabetes medications in the Medicare population is 
low, which can greatly reduce CMS star ratings for managed care organizations 
(MCOs). Proactive identification of patients at risk for future non-adherence can 
provide MCOs with a selective cost-effective approach to implement adherence 
intervention programs. The study aims to develop and validate a risk assessment 
tool (Prescription Medication Adherence Prediction Tool [RxAPT]) to predict non-
adherence to diabetes medications using Medicare claims data. METHODS: Claims 
data from 2012-2013 was used; data from previous year (baseline period) was used 
to predict adherence in the next year (follow-up period). Members 65 years and 
older with diabetes diagnosis, at least one prescription for diabetes medication, no 
insulin prescription, and continuously enrolled for both the years were included 
in the study. Adherence in the follow-up year was the study outcome, defined as 
proportion of days covered (PDC) ≥ 80%. A multiple logistic regression model was 
used to identify the final model using 70% of the data and risk scores were calcu-
lated using significant predictors from the model. The remaining 30% was used for 
cross-validation using split-sample method. Data from 2011-2012 was used to test 
the temporal validity of the tool. RESULTS: Total sample included 7028 patients. 
Seven significant predictors (all from pharmacy claims) were identified and used 
in the tool. Cross-validation statistics were as follows: C-statistics= 0.74, Hosmer-
Lemeshow goodness-of-fit p< 0.05, sensitivity= 0.71, specificity= 0.66, positive predic-
was intervention (yes/no). Other control variables included were demographics, 
physician specialty, health plan, CMS Risk Score, Charlson comorbidity index and 
number of other medications. RESULTS: In total, 186 hypertensive diabetic patients, 
non-adherent to ACE-Is/ARBs (PDC< 0.8) were identified. Among these patients, 29 
patients switched to other drug classes for treating diabetes and hypertension. After 
excluding those who switched, 157 patients were included in the logistic regression 
model with 131 continuing to use ACEI/ARBs and 26 discontinuing the ACEI/ARBs. 
Intervention and comorbidity index were found to be significantly associated with 
medication discontinuation. Patients who received intervention were more likely 
to persist with ACEI/ARBs (OR: 3.56, 95% CI: 1.06-11.86). Patients with higher CCI 
were more likely to discontinue and less likely to persist with ACEI/ARBs (OR: 0.72, 
95% CI: 0.53-0.99). Other covariates were not significantly associated with medica-
tion discontinuation. CONCLUSIONS: The brief pharmacist call was effective in 
preventing medication discontinuation. Future longer term studies are warranted 
to evaluate the effect of such interventions with other adherence outcomes such as 
proportion of days covered (PDC) and clinical outcomes like blood pressure control.
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OBJECTIVES: To determine patterns of learning diabetes care and how this impacts 
medication adherence among respondents with diabetes prescribed oral antidia-
betic (OAD) medications. METHODS: The Medical Expenditure Panel Survey (MEPS) 
household component full year consolidated data files (2010-2012) identified diabetes 
respondents (≥ 18 years) who received OAD medications and participated in the MEPS 
Diabetes Care Survey (DCS). Two groups were created from all eligible respondents 
based on how they learned diabetes care: 1) from a single primary care provider or 
medical specialist resource versus 2) multiple resources (medical provider plus inter-
net and/or group classes). OAD medication adherence was measured using the medi-
cation possession ratio (MPR). Respondents with MPR ≥ 0.8 were defined as adherent. 
Logistic regression identified significant socioeconomic factors associated with the 
learning approach (single provider versus multiple resources) used to learn diabetes 
care. RESULTS: A total of 1,347 respondents (58.5%, representing 12.6 million indi-
viduals in the U.S.) and 772 respondents (41.5%, representing 8.9 million individuals 
in the U.S.) learned about diabetes care from single resource and multiple resources 
respectively. Respondents reporting ages younger than 65 years, college degrees, high 
income levels, and treated with diet modification were more likely to learn diabetes 
care from multiple resources. No significant difference in MPR was observed between 
respondents learning diabetes care from a single provider resource (MPR= 0.66) versus 
multiple resources (MPR= 0.64, p= 0.245). Less than 45% of the respondents in both 
groups (single provider resource: 42.6%, multiple resources: 40.2%, p= 0.352) were 
adherent to OAD medications. CONCLUSIONS: Age, income and education levels, 
and whether being treated with diet modification influenced the approach to learning 
about diabetes care. Using medical providers only or multiple resources to learn about 
diabetes care had no impact on the OAD medication adherence.
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OBJECTIVES: To examine the effect of a brief pharmacist telephone intervention on 
adherence to ACE-Is/ARBs among non-adherent hypertensive patients with diabetes 
enrolled in a Texas-based Medicare Advantage plan. METHODS: The health plan 
medical claims data was used to identify patients with hypertension and diabetes 
diagnoses and at least 2 fills for ACE-Is or ARBs between January/2013-October/2013. 
Patients who failed to refill their medication for more than one day, and had a pro-
portion of days covered (PDC) < 0.8 were considered non-adherent and contacted 
by a pharmacist by phone. Descriptive statistics were conducted to assess the fre-
quency distribution of sample demographic characteristics at baseline. A multiple 
linear regression was conducted to assess the intervention effect on adherence 
during the 6 months post-intervention. The outcome variable was 6-month post 
intervention PDC. Other control variables included were baseline PDC, demograph-
ics, physician specialty (primary care vs. specialist), health plan (low income subsidy 
vs. not), CMS Risk Score, Charlson comorbidity index and number of other medica-
tions. RESULTS: A total of 131 patients were included in the analysis with 66 in the 
intervention group. The mean post intervention PDC for the intervention group was 
0.58 (SD±0.26) and 0.29 (SD±0.17) for the control group. Intervention was a significant 
predictor of better adherence in the linear regression model after adjusting for all 
the other baseline covariates (β = 0.318, p< 0.001), but the post intervention PDC was 
still lower than the generally accepted PDC of 0.8. Other covariates were not sta-
tistically significant. CONCLUSIONS: The brief pharmacist telephone intervention 
resulted in significantly better PDCs during the 6 months following the intervention 
but the overall PDC rates in both the intervention and control groups remained low. 
Future research should investigate the impact of behavior modifications which 
incorporate motivational interviewing and determine if this leads to a sustainable 
behavioral change and improved adherence.
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well-being. Exenatide: no PRO US/EU label claims sought. Lorcaserin: PRO-data 
supported US-approval (no label-claim). PRO-data supported MA for the UK and 
US. Key findings from payer interviews (n= 6 EU/n= 4 US) revealed that health-
care-system differences influence payer-preferences for PRO-type (e.g., generic/
disease-specific), influenced primarily by need for cost-effectiveness model. All 
payers stated that PRO-data provide unique perspective on condition/treatment 
but considered reimbursement difficult to influence; although stated that PRO-data 
can positively impact prescribing/MA. Payers reported that in EU, PROs are part of 
the clinical-evidence considered by HTA reviewing committees. Utility data derived 
from generic instruments are essential for key EU-markets (excluding Germany). 
US health plans are interested in PRO measures that are tied to “actionable” end-
points (e.g., adherence/persistence, tolerability, reduction in costs or resource 
utilisation). CONCLUSIONS: Key drivers for a successful PRO strategy include the 
development of robust PRO and communication strategy tailored to the needs/
requirements of the end-users (regulators, HTA and MA). Sponsors must continue 
to bring data based on robust PROs to regulators, HTA and MA and thus bringing 
the patient, the most affected stakeholder, to the forefront in decision making.
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OBJECTIVES: To assess current status of disease control and treatment satisfaction 
in patients with acromegaly in the United States. METHODS: A web-based cross-
sectional survey was conducted from August –October, 2014. Acromegaly patient-
reported information on treatment satisfaction and preference, symptom control, 
and comorbidities were collected and analyzed descriptively. RESULTS: A total of 
106 patients completed the survey (mean age: 46 years, female: 76%). Patients had 
a 5-year diagnosis delay after symptom onset. Most patients (91%) had undergone 
surgery. Of 68 patients on pharmaceutical therapy: 79% were on somatostatin ana-
logs, 22% on dopamine agonists and 13% on GH-receptor antagonists. Almost half 
of the patients (47/106) presented with 5 or more comorbidities (depression 57%, 
hypertension 43%, musculoskeletal and connective tissue abnormalities 42%, sleep 
apnea 37%, cardiac and cardiovascular diseases 32%, and diabetes 32%). There were 
96 (91%) patients reporting acromegaly-related symptoms (e.g. headache, excess 
sweating, and joint pain). As compared with the low-symptom group 0-3 (n= 41), the 
high-symptom group with 4+ symptoms (n= 65) were more likely to have depression 
(OR= 2.33, 95% CI, 1.05-5.19) and cardiovascular disease (OR= 5.80, 95% CI, 2.02-16.67). 
Among patients on injectables (n= 61), 61% had worse symptoms toward the end of 
injection cycle, and 38% requested medical intervention (i.e. additional daily injec-
tion, unscheduled injection, or oral medicines). 84% of patients reported that the 
symptoms interfered with daily life and work; 85% felt frustrated. The treatment 
satisfaction rate was 56%; 33% didn’t like having injections. The top patients’ prefer-
ences for new acromegaly treatments were to avoid injections (e.g., oral formula-
tion) (85%), improve disease management such as patients’ support (62%), and to 
provide better patient education (57%). CONCLUSIONS: More than 40% of patients 
were not satisfied with their current treatment for acromegaly. Patients want better 
therapy (e.g., oral drugs), improved disease management, and education programs.
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OBJECTIVES: The present study aimed to assess the dietary knowledge, myths and 
misconceptions among diabetic patients in Quetta, Pakistan. METHODS: The study 
was conducted as a cross sectional, questionnaire based study covering diabetic 
patients in public and private hospitals and diabetic clinics of Quetta city, Pakistan. 
A self-administered questionnaire was used evaluate the dietary knowledge, myths 
and misconception about diabetes. The questionnaire constructed with a total of 20 
(10 questions each for dietary knowledge, myths and misconception). Continuous 
variables were expressed as mean ± SD, and categorical variables are represented 
in frequency and percentage. RESULTS: A total of 400 questionnaires were dis-
tributed out of which 320 were received and included in the study. The study is 
dominated with male respondents (59.7%, n= 191), with majority (37.2%, n= 119) 
categorised in age group between 25-34 years and married (78.4%, n= 251) with 
education level as S.S.C (matriculation) (39.1%, n= 125). The mean dietary knowledge 
score was 4.81± 1.2 and myths and misconception score was 3.32± 1.8 both catego-
rised as poor. CONCLUSIONS: The study concluded that diabetes patients has poor 
knowledge regarding dietary knowledge and has high prevalence of dietary myths 
and misconceptions. Patients should be educated for proper dietary changes to be 
adopted for better disease control.
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OBJECTIVES: An important characteristic of successful healthcare and patient 
participation in clinical trials is strong communication between patients and 
their providers. Using e-clinical technology can be one mechanism for achieving 
this goal. We propose that the optimal implementation considers patient prefer-
ence and ease of use, and that incorporating e-clinical technology can lead to 
increased patient compliance and ultimately improved clinical care. METHODS: 
We surveyed 105 patients in the U.S. with diabetes; questions focused on mobile 
technology use, perceptions, and preferences. RESULTS: Patients were diverse in 
tion value= 0.75, and negative prediction value= 0.62. Temporal validation showed 
decrease in the sensitivity (0.69) and specificity (0.60) statistics. CONCLUSIONS: 
RxAPT shows promise as an effective tool to identify patients who are likely to 
become non-adherent to diabetes medications in the follow-up year. Further valida-
tion is needed before the tool can be implemented in a real world setting.
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OBJECTIVES: This study describes the relationship between health-related quality of 
life (HR-QoL) assessed using the SF-36v2 and adherence as measured by the Morisky 
Medication Adherence Scale (4-item MMAS-4 , 8-item MMAS-8, and a 4-item scoring 
of the MMAS-8) among US adults with type 2 diabetes (T2D). METHODS: Data were 
taken from the 2011 and 2012 US National Health and Wellness Survey (NHWS). The 
NHWS is a large cross-sectional survey representative of the total adult population 
in several major markets; N~75,000/year in the US. A total of 13,007 respondents 
self-reported physician diagnosis of T2D and were administered MMAS-4 in 2011 
or MMAS-8 in 2012. The relationship between SF-36v2 measures and adherence 
was described for the two adherence scales and also a scoring of the MMAS-8 that 
uses only the 4 items best matched to the questions in the MMAS-4. RESULTS: In 
T2D patients, MMAS-4 resulted in a greater percentage of respondents classified as 
having high adherence than MMAS-8 (64% vs. 44%) and a lower percentage of low 
adherence (3% vs. 19%), while medium adherence was fairly similar (33% vs. 37%). 
The 4-item scoring of the MMAS-8 was more similar to MMAS-4 (79% high, 15% 
medium, 6% low). In OLS regressions controlling for sociodemographic characteris-
tics (e.g. age, gender, comorbidities, education, income), all measures of adherence 
were significant predictors of HR-QoL, with two main differences: R-squared values 
were slightly lower for regressions including MMAS-4 adherence and MMAS-4 was 
not predictive of Physical Component Summary (PCS) scores. CONCLUSIONS: All 
three adherence scores are significantly correlated with the Mental Component 
Summary and SF-6D health utility scores of the SF-36v2, MMAS-4 fails to correlate 
with PCS. The variation in proportion of patients classified as highly adherent across 
scales also suggests pooling such classifications across data using different versions 
of the MMAS is not advisable, at least among T2D patients.
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OBJECTIVES: Type 2 diabetes (T2D) is a chronic condition with well-described long-
term cardiovascular consequences and other co-morbidities. This study investigated 
the short-term impact of poor glycemic control on T2D patients’ daily lives to help 
define the health states for inclusion in a time trade off study (TTO). METHODS: 
Adult respondents in Denmark receiving medical treatment for T2D, and knowing 
their HbA1c level, completed an online survey based on results from prior telephone 
interviews with patients to identify perceptions on weight, simplicity of insulin 
regimen and aspects of well-being affected by change in HbA1c. Questions covered 
demographics and insulin regimen, most recent HbA1c and change from previous 
HbA1c, how often they experience certain physical and psychological symptoms 
(1–5 with 1= never and 5= always), if respondents wanted to reduce HbA1c, and the 
extent to which key criteria were felt to prevent reducing HbA1c (1–5 with 1= full 
extent and 5= not at all). RESULTS: 268 respondents (72% men, mean age 66.5 years) 
completed the survey. Average change in HbA1c was 2.0%. Frequency of excessive 
thirst reduced significantly with a > 1% drop in HbA1c and the effect increased with 
further decreasing HbA1c. Similar results were found for frequency of urination. 
Fatigue and lack of energy also improved with decreasing HbA1c. Almost 100% 
of respondents with HbA1c ≥ 9% wished to reduce their HbA1c, compared to 61% 
with HbA1c < 7%. Answering “to what extent does the following explain why your 
HBA1c is not lower?”, the highest response was ‘to avoid gaining weight’, lowest 
response was ‘forgetting to take medication’. CONCLUSIONS: Symptoms improve 
with reduced HbA1c, and the majority of respondents wish to lower their HbA1c. 
Changes in HbA1c are perceived to have a major impact on daily lives; however, 
there are still a variety of barriers preventing people with T2D from lowering their 
HbA1c.
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OBJECTIVES: To identify key drivers for the successful integration of patient-
reported outcomes (PROs) in clinical programs designed to support regulatory label 
claims, health technology assessment (HTA) and market access (MA) in diabetes 
and obesity. METHODS: Reviews of published literature, regulatory, HTA and third-
party websites were conducted to elicit key components of PRO strategies employed 
for two case examples: exenatide (diabetes) and lorcaserin (obesity). Qualitative 
one-on-one interviews were also conducted with payer decision-makers in key 
European (EU) and United States (US) markets to determine their perceptions of 
successful PROs strategies. RESULTS: Although there is an FDA draft guidance on 
PROs to support labeling claims, no disease-specific guidance on PRO-endpoints 
for obesity/diabetes are issued by FDA or EMA. Registration-trials included assess-
ments of; symptoms/health-related-quality-of-life/depression/psychological-
